CASI Pharmaceuticals, Inc.
CASI
$0.94
$0.010.88%
NASDAQ
| 09/30/2025 | 03/31/2025 | 12/31/2024 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 31.37M | 28.54M | 28.54M | 22.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 31.37M | 28.54M | 28.54M | 22.06M |
| Cost of Revenue | -- | 18.41M | 17.39M | 17.39M | 10.08M |
| Gross Profit | -- | 12.96M | 11.15M | 11.15M | 11.98M |
| SG&A Expenses | -- | 44.81M | 41.44M | 41.44M | 41.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -7.00K | -2.00K | -2.00K | -5.06M |
| Total Operating Expenses | -- | 71.59M | 67.75M | 67.75M | 53.68M |
| Operating Income | -- | -40.23M | -39.21M | -39.21M | -31.62M |
| Income Before Tax | -- | -40.48M | -39.26M | -39.26M | -30.78M |
| Income Tax Expenses | -- | -- | -- | -- | -1.00K |
| Earnings from Continuing Operations | -- | -40.48 | -39.26 | -39.26 | -30.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -163.00K |
| Net Income | -- | -40.48M | -39.26M | -39.26M | -30.94M |
| EBIT | -- | -40.23M | -39.21M | -39.21M | -31.62M |
| EBITDA | -- | -37.19M | -35.82M | -35.82M | -27.88M |
| EPS Basic | -- | -2.51 | -2.53 | -2.53 | -2.23 |
| Normalized Basic EPS | -- | -1.65 | -1.67 | -1.67 | -1.48 |
| EPS Diluted | -- | -2.51 | -2.53 | -2.53 | -2.23 |
| Normalized Diluted EPS | -- | -1.65 | -1.67 | -1.67 | -1.48 |
| Average Basic Shares Outstanding | -- | 63.46M | 61.35M | 61.35M | 55.57M |
| Average Diluted Shares Outstanding | -- | 63.46M | 61.35M | 61.35M | 55.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |